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1. Introduction
Colorectal cancer (CRC) is the third most frequently diagnosed cancer in both men and women
and the second leading cause of cancer death after lung cancer. Even though CRC is considered
to be 90% curable if detected in early stage, the majority of patients are diagnosed with
advanced stages, III or IV [1].
Screening tests applied according to well known strategies make the early diagnosis of CRC
possible and there is is strong evidence evidence that screening lowers mortality and incidence
rates of cancer, if recommended at proper time in people at risk [2]. Still, the existing tests
practiced on a large scale in CRC screening do not fully accomplish the goal of best specificity
and sensitivity or either an optimal cost/efficiency ratio. A more effective screening test may
significantly decrease disease burden.
Extensive research over the past two decades provided large information about genetic
aberrations underlying CRC and revealed complex and heterogeneous mechanisms in the
occurrence of the disease [3, 4]. Genetic changes occurred in normal colonic epithelium cells
promoting the neoplastic transformation into benign adenomas and subsequently malignant
adenocarcinomas were the essence for understanding the disease behavior and related clinical
outcome, and created a perspective for future improvements in diagnosis, treatment and
survival rates.
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Colorectal cancer genesis — Gene mutations and underlying stool testing
A cancer cell develops through a collection of gene mutations. Mutations left uncorrected by
cell cycle regulation before division are fixed in that cell and in its future progenitors. A cell
undergoes full carcinogenic transformation once a sufficient number of genes are mutated and
the cell can no longer respond to the external signals that act as brakes on cell growth.
Comparing with breast cancer, in which a single gene is required for disease initiation, in CRC
there are 7 to 10 genes responsible for neoplastic transformation and thereforee, the genetic-
based screening for CRC is a more laborious task than screening breast cancer [5].
Although a smaller subgroup can arise as a result of inherited mutations or previous inflam‐
matory bowel disease (Crohn’s disease or ulcerative colitis), the great majority of CRC arise
sporadically. This means that mutated genes are present only in precancerous and cancerous
lesions in the colon and rectum, and are not present in all cells of the body. Therefore, CRC
cannot be detected by a blood test, as breast cancer does [6].
Over the time, mutations of three different classes of genes have been described in colon cancer
etiology: oncogenes, suppressor genes, and mismatch repair genes [7]. Knowledge of many of
the specific mutations responsible for colon carcinogenesis allowed understanding the
phenotypic manifestations and provided a large field for genetic testing from stool cell’s DNA
[8]. Although genetic testing is possible and available, it is not yet clear what battery of genetic
tests are more accurate to use as an alternative diagnostic tool instead present widely accepted
stool test.
Until now, the genetic changes targeted in the stool cell’s DNA involved in the development
of some colorectal cancers included: activating mutations of the K-RAS oncogene, inactivating
mutations of the adenomatous polyposis cancer (APC) and TP53 tumor suppressor genes [9]
and germline or somatic mutations of mismatch repair genes (MMR) [10, 11].
A much less studied biomarker targeted in stool samples for early diagnosis of CRC in patients
at risk is COL11A1 gene, mutations of which have been first described in Marshall’s syndrome
and Stickler’s syndrome [12]. The normal function of this gene is the production of collagen
type XI, which participate to build the structure and the resistance of conjunctive tissues. Beside
its main role in the assembly, organization and development of cartilage, COL11A1 was found
to be expressed at low level in a wide variety of normal adult human tissues, including lung,
parotid gland and colorectal cells.
Few studies have found overexpression of the COL11A1 gene in various types of cancers, such
as non-small cell lung cancer (NSCLC), ovarian, oral cavity and colorectal cancers. In partic‐
ular, overexpression of the COL11A1 gene was found to be correlated with invasive and
metastatic potential of these cancers [13-16].
This gene is located on chromosome 1, arm p, site 21, between the 103.055.015 and 103.286.072
pair of bases, and is composed of 231 kbase. It contains 68 exons, not yet wholly sequenced [17].
A major contribution to the COL11A1 gene sequencing knowleddgee, especially with the
purpose of detecting mutations, is Annune S research and results [18]. Recent extented studies
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demonstrated that some polymorphysms of COL11A1 are associated with different types of
adenocarcinoma [19].
3. AIM
This study was designed to analyze COL11A1 gene mutations identified in the DNA of
exfoliated epithelial cells of the colon in the stool of the patients diagnosed with CRC through
screening and to demonstrate the perfect similarity between the detected mutations in tumor
samples and in exfoliated stool cells, in order to prove the reliability of the method as a
diagnostic tool for early CRC diagnosis.
4. Patients and method
We selected 250 patients diagnosed in the Endoscopy Department of Emergency Hospital of
Constanta with adenomatous polyps and CRC using colonoscopy and biopsy and confirmed
by histopathological exam, during screening programme or admitted and investigated for
intestinal disturbances such as chronic diarrhea or recent exacerbated constipation, stool
bleeding or association of the above symptoms in their recent history.
We collected samples biopsied from tumors during colonoscopy and stool sample from each
patient.
Colonoscopy and biopsies were performed with Olympus Exera equipment.
The bowel preparation was done according to guidelines and its quality was noted.
The colonoscopist documented the presence, size, location and extension of colonic tumors.
Biopsy or surgical resection samples were examined histopathologically and genetically.
Subjects were instructed prior stool collection. No dietary or medication modifications were
required. Until shipping samples to genetic lab, these were disposed in a coded container into
a refrigerator, between 0 and 4°C. Specimens were required to arrive within 3 days after
collection.
The minimum quantity of stool sample required was 30 g. Samples were stored at –80°C until
genetic analysis.
DNA was extracted from biopsy and feaces samples for mutation analysis:
• from stool, with QIAmp stool extraction kit (QIGene, Germany);
• from biopsy sample, with IQ-DNA Extraction Kit (Promega USA).
Primers for PCR amplification were provided by TIB MOLBIOL, Germany.
The COL11A1 gene, examined in the present study, produces a component of the colagen type
XI, named pro-alpha1 chain, an important factor for connective tissue structure and resistance.
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The method used for COL11A1 mutations was polyacrylamide gel electrophoresis method for
the heteroduplex analysis (HA).
Investigation of COL11A1 gene is made sequentially by setting fragments to be analyzed. To
do this, fragments that usually carry most mutations are identified. Each fragment of COL11A1
gene that is proposed for investigation is amplified by PCR. For this, primers flanking each
particular fragment are used.
PCR conditions are dependent on the characteristics of each pair of primers. Each program
contains a PCR initial denaturing step, lasting for 3 minutes at 94°C, followed by 30-35 reaction
cycles (depending on the length of the fragment of interest and the size and composition of
the primers), each cycle comprising: denaturation, alignment, elongation (conditions are
established for each pair of primers used), and the final elongation step, lasting for 5 minutes
at 72°C. Obtained amplicons are subjected to additional steps of forced denaturation-renatu‐
ration (to encourage heteroduplex formation), and then migrated in a 6% polyacrylamide gel.
The heteroduplex is represented by a fragment of double-stranded DNA in which the two
strands do not express perfect complementarity. When DNA is denatured, the two strands are
separated. Through renaturation, complementary chains come together to form a homodu‐
plex. If there is a mutation in one of the two strands, heteroduplex is formed (figure 1).
Heteroduplex analysis was imagined by Ziemmermann et al in 1993 [20] and has been used to
enhance the sensitivity of denaturing gradient gel electrophoresis (DGGE) in the detection of
point mutation [21-23]. DNA fragments for HA can be visualized via a variety of methods
including bromide staining, labelling with radioisotopes and silver staining. The mutations
detection rate of HA under ideal conditions is near 90%.
Heteroduplex differ from homoduplex by electrophoretic migration speed in polyacrylamide
gel. Mutational alteration of a single base pair is sufficient to produce changes in mobility.
Electrophoretic mobility of heteroduplex is lower than that of homoduplex, and it can be
detected as a slower migrating band. This method can detect insertions, deletions and
substitutions of even a single base pair in fragment lengths smaller than 200 bp.
The working protocol for this technique is very simple and quick and consists of a denatura‐
tion-renaturation step for which we set the following conditions: 94°C – 1 minute, 72°C – 1
minute, 65°C – 1 minute, 40°C – 1 minute and thermal shock at 4°C. Each stage is covered by
one cycle. The existence of deletion mutations will result in the formation of four bands, two
heteroduplex and two homoduplex (heterozygous condition) (Figure 1).
Migration occurs differently based on molecular weight. Samples from patients and healthy
individuals (control samples) are migrated in the same gel, in order to analyze the difference
in migration. If the investigated individual is a normal homozygous or a homozygous for
analyzed mutation, a single band will be displayed in each case. The difference between these
conditions is based on different migration and reported to the molecular weight marker used.
If there is a substitution mutation, two bands are visualized on polyacrylamide gel: a band
representing heteroduplex and a band representing homoduplex. In this case, the difference
in migration is explained on the basis of different chemical composition of the four DNA
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strands. For optimal view of amplification products, we used 6% polyacrylamide gel, con‐
taining 0.5 μg ethidium bromide, migrated 6 V/cm. The gel is observed and photographed on
UV transilluminator.
In the latter stages of a PCR amplification the polymerase is limiting, so that during the final
annealing and synthesis steps, a proportion of the single stranded products spontaneously
reanneals without primer extension. When amplifying from individuals heterozygous for any
sequence difference, the single strands do not necessarily rehybridize exactly with the
complementary strand. They can alternatively form a DNA hybrid (heteroduplex) consisting
of a sense strand with one sequence variant and an antisense strand with another variant.
As a consequence, the heteroduplex DNA has a region of at least one base pair mismatch. The
region of mismatch can elicit a mobility shift by altering the conformation adopted by the
heteroduplex DNA, probably by causing it to bend at the location of the mismatch. The
mobility shifts are usually small but can be visualized after prolonged electrophoresis on native
polyacrylamide gels.
Figure 1. Denaturation and renaturation of normal and mutated DNA fragments in order to generate four types of
fragments: two heteroduplex and two homoduplex. Fragments were migrated parallel on denaturating gradient gel.
“Melting” heteroduplex are modified in the sense that they denaturate at a lower concentration of denaturant, allow‐
ing their visualization.
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1. Detection of COL11A1 gene mutations included the following steps:
2. Genomic DNA extraction from the analyzed samples: tumor tissue obtained through
biopsy and exfoliated cells from feces;
3. Amplification of the interested gene amplicons through PCR reaction;
4. Amplification check up through electrophoresis in agarosis gel and bromide ethidium
staining;
5. Mutations identification through DGGE technique and silver or ethidium bromide
staining.
5. DNA extraction from proposed samples
DNA extraction from stool has been made by a specific kit for stool extraction [24, 25]. DNA
tissue extraction from the colorectal biopsy has been performed using DNA IQ (TM) System
kit [26]. DNA IQ (TM) System kit uses the principle of DNA extraction based on a paramagnetic
resine. In addition, the kit contains a series of denaturating agents (“lysis buffer”), having the
role of disintegrating the biologic product that is the DNA source.
An important advantage of this kit is that it provides extraction of an optimal DNA quantity
for PCR reaction (100 ng/μl).
6. DNA extraction from stool
DNA extraction from stool was performed with a kit designed for extraction from faeces
(QIAGEN GmbH, Hilden Germany). The technique included the following steps:
1. 200 mg of faeces were suspended in 2 ml of ASL buffer by vortexing for 1 minute.
2. 1.6 ml of this lysate was transferred to a new tube.
3. Suspension was boiled for 5 minutes.
4. Centrifuged at maximum speed for 1 minute.
5. Transfered 1.2 ml of supernatant into a new tube containing an InhibitEX tablet.
6. Vortexed the tube for 1 minute and incubated for 1 minute at room temperature.
7. Centrifuged the tube for 3 minutes.
8. Transfered 200 μl of supernatant into a new tube containing 15 μl of proteinase K.
9. Added 200 μl of Buffer AL and vortex.
10. Incubated at 70°C for 10 minutes.
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11. Added 200 μl of ethanol to lysate and vortex.
12. Content was applyed in a column of centrifugation and centrifuged at 10,000 x g for 1
minute.
13. The column was washed once with 500 μl of Buffer AW1 at 10,000 x g for 1 minute and
then with 500 μl of Buffer AW2 at 10,000 x g for 1 minute.
14. DNA was eluted from the column at 10,000 x g, 1 minute, with 100 μl heated buffer AE.
7. DNA tissue extraction from colorectal biopsy
DNA extraction from biological product was performed with DNA kit IQTM System, manu‐
factured by Promega, USA. DNA IQTM System is a kit that uses a new DNA extraction
principle based on the use of paramagnetic resin. In addition, the kit contains a number of
denaturating agents (“lysis buffer”) which are designed to disintegrate biological product that
is the source of DNA.
For some biological products (hair, tissue) which are resistant to this type of disintegration, an
additional pretreatment with proteinase K is used, an enzyme that produces sample lysis.
A considerable advantage of this kit is that it provides an optimal quantity of DNA extraction
for PCR reaction, respectively 100 ng/μl, regardless of used biological product.
Used magnetic resin binds only a limited amount of DNA even if it is in excess. Finally, DNA
is eluted from the resin with 100 μl of eluent solution yielding a final concentration of 1 ng/μl.
Thus, it is no longer necessary to quantify the amount of extracted DNA.
In principle extraction kit use the following steps:
• Extraction of the sample and its lysis;
• Resin-capture DNA;
• Magnetic resin-washing;
• Elution of DNA from the resin.
8. Purification of DNA from a tissue sample
1. We place about 1 mg of tissue in a 1.5 ml tube.
2. We added 50-100 μl of incubation buffer solution/freshly prepared proteinase K and
incubated at 56°C for 2 hours. Usually all tissue is digested after 2 hours, and if it doesn’t
occur, incubation is extended.
3. We removed the source sample incubation and added 2 volumes of lysis buffer.
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4. We added 7 μl of magnetic resin. The sample was vortex 3 seconds and left at room
temperature for 5 minutes.
5. Then the simple was vortex for 2 seconds and left the tube on the magnetic stand.
Separation occured instantly.
6. Carefully we aspirated all the solution without disturbing the resin at the bottom of the
tube.
7. We add 100 μl of prepared lysis buffer. We removed the tube from the magnetic stand
and vortex 2 seconds.
8. Placed the tube again on the magnetic stand and vacuum lysis buffer.
9. Added 100 μl of Wash Buffer preparation. We removed the tube from the magnetic stand
and vortex 2 seconds.
10. We replaced the tube in the magnetic stand and aspirated the solution.
11. We repeated steps 9 and 10, 2 times to make a total of three washes.
12. Tubes were allowed in the magnetic stand with the lid open for 5 minutes to dry.
13. We added 25-100 μl of elution buffer, depending on the amount of biological material
used.
14. Then we closed the lid and vortexed 2 seconds. We incubated at 65°C for 5 minutes.
15. Removed the tube from the heating device, vortexed 2 seconds and immediately puted
the tube on the magnetic stand.
16. Finally, we aspirated DNA containing solution and left the tube in conservation.
9. Validation of human origin of DNA extracted from stool by STR loci
typing
The analysis of the nuclear DNA extracted from stools is a recent new method for CRC
diagnostics.
In the preliminary phase of our study, we comparatively analyzed the DNA extracted from
the biopsy samples of the patients with the DNA extracted from the stool samples of the same
patients. This comparative analysis was performed by investigating a number of 9 human STR
loci, frequently used in the DNA typing techniques of forensic medicine.
The STR type loci (“short tandem repeat” or “microsatellite repeats”) contain 4 bases of
segments that repeat 5-50 folds, depending on the loci. These STR are of a very small size
(100-400 bases) and are very useful for the degraded DNA analysis. These repetitive sequences
are largely spread in the human genome, being a rich source of polymorphic markers that may
be detected through PCR.
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For the DNA typing in our cases, we used a number of 9 STR loci. Determination of the 9 loci
can be made by using kits of molecular biology, forming GenePrintSTR Systems of Multiplex
type.
10. Amplification of the interested gene amplicons through PCR reaction
Primers the analysis of all the 68 exons of COL11A1 gene are not yet available. We managed
to obtain sequence for primers of two groups of amplicons containing amplified segments in
exons where most frequently mutations in various cancers were found.
Amplification groups are:
• Group 1:
◦ Amplicon 38;
◦ Amplicon 41;
◦ Amplicon 16.
• Group 2:
◦ Amplicon 54;
◦ Amplicon 55;
◦ Amplicon 56;
◦ Amplicon 57.
PCR reactions were done simultaneously for each of the two groups above. We used PCR
amplification kit manufactured by Promega (USA) called “PCR Core System”. It was designed
to enhance any type of amplicon, by usind standard type Taq polymerase.
Materials required:
• Thermal cicler for 0.2 ml tubes;
• microcentrifuge;
• Taq DNA polymerase;
• Nucleases-free water;
• Mineral Oil;
• 0.2 ml Amplification tubes;
• 1.5 ml microcentrifuge tubes;
• Anti-aerosol pipette tips;
• Ice.
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11. Thermal cycling protocol
Manufacturing company recommends several types of thermal cycling protocols and the
choice depends on the thermo-cicler and optimized version that has been established. We have
optimized the following protocol – protocol COL11A1:
• Step 1: 94°C, 1 minute;
• Step 2: 52°C, 1 minute;
• Step 3: 72°C, 1 minute;
Repeated successive steps 1, 2 and 3, in 5 cycles.
• Step 4: 94°C, 1 minute;
• Step 5: 50°C, 1 minute;
• Step 6: 72°C, 1 minute;
Repeated successive steps 4, 5 and 6, in 5 cycles.
• Step 7: 94°C, 1 minute;
• Step 8: 48°C, 1 minute;
• Step 9: 72°C, 1 minute;
• Step 10: 72°C, 3 minutes;
• Step 11 (rest): 4°C.
12. Amplification setting
To prevent contamination it is strongly recommended the use of gloves and anti-aerosol
pipette tips. Maneuvers that must be cosidered are as follows:
1. Defrost kit components and pairs of primers and then put them on ice.
2. Mark each 0.2 ml amplification tube and place it in the stand.
3. Determine the number of reactions to be performed. This number must include the
positive and negative control reaction, respectively. Add to this number another 1-2
reactions in addition, to compensate for pipetting errors.
4. Prepare the amplification (PCR Master Mix) solution, according to the table below (table
1). Multiply the volume per sample (μl) with the total number of reactions, to obtain the
final volume.
Colorectal Cancer - Surgery, Diagnostics and Treatment412
PCR Master Mix Component Volume per sample (μl)
MgCl2 25 mM sol. 1.5
10X Buffer Taq DNA Polymerase 2.5
PCR Nucleotide mix, 10 mM 0.5
“Primer Upstream”, 15 μM 1.65
“Primer "Downstream”, 15 μM 1.65
Taq DNA Polymerase (at 5 u/μl) 0.12
Distilled water without nucleases 17.08
Total volume 22.5
Table 1. Preparation of PCR Master Mix.
1. In order from above table lay the final volume of each reagent in a sterile tube. Shake
gently (not vortex) and place the tube on ice.
2. Add 22.5 μl of PCR Master Mix to each reaction tube and place tubes on ice.
3. Pipette 2.5 μl of each DNA sample to respective tubes containing 22.5 μl of PCR Master
Mix.
4. Pipette 2.5 μl (5 ng) of K562 DNA (diluted to 2 ng/μl) in a reaction tube containing 22.5
μl of PCR Master Mix, which is a positive control.
5. Pipette 2.5 μl of sterile distilled water (instead of DNA) in a reaction tube containing 22.5
μl of PCR Master Mix, which is a negative control.
6. Add 1 drop of mineral oil to each tube. Close the tubes.
7. Centrifuge tubes to bring the contents to the bottom of the tube.
8. Assemble the tubes in thermal triggers cicler and start amplification.
9. After amplification, the tubes must be kept at –20°C.
12.1. Electrophoresis of amplified samples for evidence heteroduplex
For this complex electrophoresis technique, we used a device type “DCode Universal Mutation
Detection System” manufactured by Bio-Rad (Germany).
12.2. Formation reaction of heteroduplex
Protocol consists of a denaturation-renaturation step of PCR sample obtained from normal
witness mixed with PCR sample from analyzed patient was established under the following
conditions:
• 94°C – 1 minute;
• 72°C – 1 minute;
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• 65°C – 1 minute;
• 40°C – 1 minute;
• heat shock at 4°C.
Heteroduplex are generated by adding to the same PCR reaction the mold of mutant and
normal DNA, or by PCR product mixing, denaturation and ultimately their renaturation. A
heteroduplex contains a mismatch base in the double chain, causing a distortion in its confor‐
mation; bands containing heteroduplex always migrates more slowly compared to bands
containing homoduplex.
12.3. Preparation of reagents
Acrylamide concentration used generally depends on the sample to be analyzed, and we used
a 40% stock solution containing acrylamide and bis-acrylamide.
• Acrylamide/Bis – 40% (37.5:1);
• Acrylamide – 38.9 g;
• Bis-acrylamide – 1.07 g;
• Water dist. – ad. 100 ml.
In the table below (table 2) we present the concentration of acrylamide/bis used to separate
different DNA molecules:
Gel concentration Separation of base pairs
6% 300-1000 bp
8% 200-400 bp
10% 100-300 bp
Table 2. Concentration of acrylamide/bis used to separate DNA molecules.
We worked with a solution of acrylamide/bis 6%, given the length of amplified fragments.
• Acrylamide/Bis solutions, 6% (1.25 x TAE, 6M urea);
• Acrylamide/Bis 40% 6.0 ml;
• 50X TAE buffer 1 ml;
• Urea 14.4 g;
• TEMED 40 μl;
• Ammonium persulfate 10% 400.0 μl;
• Total volume 40 ml.
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We added water to 40 ml. Pour gel immediately after adding TEMED and ammonium
persulphate.
• 50X TAE buffer:
◦ Tris base 242.0 g;
◦ glacial acetic acid 57.1 ml;
◦ 0.5M EDTA, pH 8.0, 100 ml;
◦ water dist. ad. 1000 ml.
• Ammonium persulfate 10%:
◦ ammonium persulfate 0.1 g;
◦ water dist. 1 ml;
• Staining solution DCode;
◦ bromophenol blue 0.05 g;
◦ xylene cyanol 0,05 g;
◦ 1X TAE buffer 10 ml;
• Solution for implementing samples:
◦ bromophenol blue 0.25 ml 2%;
◦ xylene cyanol 0.25ml 2%;
◦ glycerol 7.0 ml;
◦ water dist. 2.5 ml;
• 1.25 X TAE buffer migration:
◦ 50X TAE buffer 175 ml;
◦ water dist. 6825 ml.
13. Sample preparation
1. It is important that PCR is optimized to decrease the formation of artifact products that
may interfere with test itself. PCR products should be assessed for purity by agarose gel
electrophoresis before being used for electrophoresis.
2. On gel we applied 180-300 ng of amplified DNA per well. On each gel and for each
amplicon there were joined migration of the sample and normal DNA.
3. At each sample, we added a volume of 2X sample application solution.
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13.1. Preheating migration buffer
1. Electrophoresis tank was filled with a quantity of 7 L of 1X TAE buffer.
2. We placed the temperature control module above the electrophoresis tank.
3. Then we adjusted the temperature to 60°C. To achieve this temperature 1-1.5 hours
wereneeded. If the buffer is preheated in the oven, this time can be reduced.
13.2. Assemble gel sandwich
Casting procedure is extremely laborious and is was done by strict electrophoresis guidelines
provided by equipment manufacturer. A system of 16x16cm plates was used and the prepared
gel was “sandwich” type.
1. “Sandwich” gel is mounted on a clean surface. We have placed large plate first, then we
have set the spacers on the short edges of this plate.
2. Lower plate was disposed over the large plate so the bottom was flush with large plate
edge.
3. We loosen the black screw of the two sandwich cutters. We placed plates in these pliers
so that the arrows were facing upwards.
4. We tightened the clamps so that the glass plates were well fixed.
5. Sandwich assembly was inserted into the alignment (without clips into place) so short
board was facing forward. We loosen the clips and clamps easily inserted between the
plates alignment plate which serves to align the spacers.
6. We aligned the plates and spacers by moving laterally and obliquely claws. We must
ensure that the spacers are perfectly parallel and the lower edge of the two plates was
perfectly aligned. We tightened the screw clamps for immobilizing overall assembly.
7. We removed the plate alignment between glass plates. Then we removed the sandwich
from the stand and check the lower edges of the plates and spacers are aligned perfectly.
13.3. Casting the gel
1. We placed the gray foam in the space provided for pouring the gel. Pins of the base were
completely relaxed. Placed plates mounted on the lower plate to the front pad. After it
was placed correctly by turning the cam, pressing the lower edge of the foam boards was
performed.
2. In a 50 ml tube we puted the required amount of gel solution. Ammonium persulfate and
TEMED were added to a final concentration of 0.09% (v/v). Stopped the tube and mixed
by inversion.
3. We inserted the comb into sandwich and positioned it so that it was slightly bent (angle)
to the edge boards. This prevented the formation of air bubbles between the gel and the
comb teeth.
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4. Poured the gel solution into the sandwich until comb teeth were covered. Then pressed
the comb in its correct position. Solution was added to the filling.
5. We allowed the gel to polymerize for 60 minutes. After polymerization we carefully
removed the comb.
13.4. Migrating samples
1. Electrophoresis tank must contain 7 liters of buffer migration.
2. After the temperature was reached by the migration buffer (60°C) we disconnected
temperature maintenance system.
3. Removed the temperature module from the electrophoresis tank. Gel fitting with gel
electrophoresis was introduced into the tank and the temperature module was placed
again into position.
4. Filled the volume of migration buffer until the level mark on the camera, and added also
into the anode upper chamber.
5. Before applying the samples we left the machine running again to reach a migration
temperature of 60°C.
6. Applied the samples after each well was previously rinsed with buffer. Sample application
was made through a specially designed device that is provided.
7. Samples prepared as described above were applyed by automated pipetting carefully so
that they do not spread outside the wells.
8. Closed the device and connected to the source. Migration was 5 hours at a voltage of 5 V/
cm.
13.5. Gel staining
Electrophoresis was performed after the gel is removed from the tank, and glass plates
carefully unfold. The gel sticks to the glass plate. Staining can be done by two procedures:
simple procedure with Ethidium Bromide and fluorescence examination or staining procedure
Argent. We opted for the second.
Protocol described below is an adaptation of that offered by the company with the Promega
kit “DNA Silver Staining System”.
A kit contains the following ingredients required for 10 stains:
• 500μl Bind silane;
• 20 G Silver Nitrate (10 x 2g);
• 60 Ml Formaldehyde, 37% (20 x 3 ml);
• 10 Ml Sodium thiosulfate, 10 mg/ml (10 x 1 ml);
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• 600 G Sodium Carbonate (10 x 60g).
13.6. Materials required
• Fixing solution/stop:
◦ 200 ml glacial acetic acid;
◦ 1800 ml distilled water;
• Coloring solution:
◦ silver nitrate (AgNO3) 2 g;
◦ 3 ml 37% formaldehyde;
◦ 2000 ml distilled water;
• Developing solution:
◦ 3 ml 37% formaldehyde;
◦ Sodium thiosulfate 10 mg/ml, (Na2S2O3 x 5H2O) 400 μl ;
◦ 2000 ml distilled water;
◦ sodium carbonate (Na2CO3) 60 g.
We prepared the solution just in time to use it, cooled at 4-10°C before use.
14. Technique used
1. Gel plates were placed on a flat surface. With a plastic “feather” glass was removed. The
gel was caught on the short board.
2. The gel attached on short plate was placed in a plastic tray.
3. Argent coloring followed few steps:
a. fixing /stop solution – 20 minutes;
b. distilled water – 2 minutes;
c. Repeat step “b” 2 times 2 x 2 minutes;
d. staining solution – 30 minutes;
e. distilled water – 10 seconds;
f. developing solution (4-10°C) up to 5 minutes (to become visible Ladder allele);
g. fixing/stop solution* – 5 minutes;
h. distilled water – 2 minutes;
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*Solution was added directly above solution developer to stop the developer reaction.
4. We placed the gel upright and dry overnight.
15. Mutations identification through DGGE technique and silver or
ethidium bromide staining
After amplification the samples were checked to confirm successful amplification by agarose
gel electrophoresis. For migration were applied two tests, one that was considered the normal
type (same in all cases) and the other representing the analyzed case.
To see if amplifyed amplicons in the studied cases presented mutations, we used samples
examined by agarose gel electrophoresis, for electrophoresis on polyacrylamide 6%.
16. Statistical analysis
Statistical analysis was performed using Graph Pad InState and Graph Pad State Mate.
17. Results
Demographic and clinical characteristics of patients examined during study period were as
follows (table 3).
Histopathological classification and localization of tumors in patients investigated through
colonoscopy and biopsy referred to genetic analysis of COL11A1 mutations can be seen in
table 4.
From the total of 250 patients genetically explored, 178 (71.20%) were diagnosed with adeno‐
carcinoma and TNM staged after hiistopathological and imagistic examinations. Most of the
patients were staged as stage II or III (18.80%, respectively 23.60%).
We analyzed 51 patients diagnosed with advanced adenomatous polyps. Polyps were
classified according to hiistopathological features in: 26 polyps with high-grade dysplasia
(10.40%), 17 villous adenoma (6.80%), and 8 tubular adenoma bigger than 1 cm (3.20%).
Among the 250 patients studied, 178 had adenocarcinomas, 51 had advanced adenomas, and
the rest 21 had minor polypspolyps.
All samples analyzed for fecal COL11A1 mutations were processed in a single laboratory.
The plan for COL11A1 analyses in feces or biopsy has been described previously and is shown
in figure 2.
COL11A1 — Genetic Biomarker Targeted in Stool Samples for Early Diagnosis of Colorectal Cancer in Patients at Risk
http://dx.doi.org/10.5772/57327
419
Characteristic No. %
Age
Mean (yr) 67.44 ± 8.97 20.40
40-49 51 31.60
50-59 79 34.80
60-69 87 9.20
70-79 23 4.00
≥ 80 10
Sex
Male 189 75.60
Female 61 24.4
Ethnicity
Caucasians 203 81.20
Other 47 18.80
Family history
APC (adenomatous polyposis coli) 16 6.40
CRC 49 19.60
Other cancer 37 14.80
Without family history of cancer/polyps 148 59.20
Table 3. Demographic characteristics of patients enrolled in the study.
Histopathological
feature No./%
Localisation – no./%
Ascendinging
Colon Transvers
Descendinging
colon Sigmoid Rectumum
Adenocarcinoma
Stage TNM I
Stage TNM II
Stage TNM III
Stage TNM IV
178/250
[71.2]
33 [13.20]
47 [18.80]
59 [23.60]
39 [15.60]
41/178
[23.03]
6 [3.37]
7 [3.93]
14 [7.86]
14 [7.86]
21/178
[11.79]
5 [2.80]
6 [3.37]
8 [4.49]
2 [2.23]
62/178
[34.83]
12 [6.74]
18 [10.11]
22 [12.35]
10 [5.61]
44/178
[24.71]
7 [3.93]
12 [6.74]
12 [6.74]
13 [7.30]
10/178
[4.00]
3 [1.68]
4 [2.24]
3 [1.68]
0 [0.00]
Advanced adenoma
High-grade dysplasia
Villous adenoma
Tubular adenoma ≥ 1cm
51/250
[20.40]
26 [10.40]
17 [6.80]
8 [3.20]
12/51
[23.52]
8 [15.6]
3 [5.88]
1 [1.96]
7/51
[13.72]
4 [7.84]
1 [1.96]
2 [3.93]
16/51
[31.72]
7 [13.72]
5 [9.80]
4 [7.84]
14/51
[27.45]
7 [13.72]
6 [11.76]
1 [1.96]
2/51
[3.92]
–
2 [3.93]
–
Minor polyps
Tubular adenoma <1cm
Hiperplastic
Unspecified
21/250
[8.40]
9 [3.60]
10 [4.00]
2 [0.8]
3/21
[14.28]
1 [4.76]
1 [4.76]
1 [4.76]
5/21
[23.80]
2 [9.52]
3 [14.28]
–
5/21
[23.80]
2 [9.52]
3 [14.28]
–
6/21
[28.57]
3 [14.28]
2 [9.52]
1 [0.56]
2/21
[9.52]
–
2 [9.52]
–
Table 4. Hiistopathological classification and tumor localization.
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I. Genomic DNA extraction from the analyzed samples 
Tumor tissue obtained through biopsy 
Purification of DNA from a tissue sample 
Exfoliated cells from feces 
Validation of human origin of DNA extracted from 
stool by STR loci typing 
II.  Amplification of the interested gene amplicons 
through PCR reaction 
III . Electrophoresis of amplified samples for 
heteroduplex evidence 
IV . DGGE analysis of COL11A1 gene mutations 
through DNA heteroduplexes 
Figure 2. Approach to Extraction and Analysis of Fecal and Tumor DNA analysis.
Also laboratory handling of all samples was fully described above.
Each exon of gene COL11A1 studied was assessed independently.
We considered a positive result any modified component of the study gene, and we noted any
mutation as a positive fecal DNA test.
18. DGGE analysis of COL11A1 gene mutations through DNA
heteroduplexes
COL11A1 is located on chromosome 1p21 and consists of 232,030 bases. It contains 68 exons,
yet not wholly sequenced, of which exons 38, 41, 16, 54, 55, 56 and 57 were until now studied.
HE analysis for exons 38, 41 and 16
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For all 3 analyzed amplicons in all 250 studied cases, the migration speed was identical for
both control and samples.
HE analysis for exons 54, 55, 56 and 57
HE analysis of exons 54 clearly demonstrated in 52 cases (20.80%) the presence of the same
displaced bands pattern in the biopsy and stool extracted cells samples compared with the
control. This pattern of mutation was correlated positively with male gender, TNM stage
II/III tumors, vegetative pattern, descendent and sigmoid localization – table 5.
No. Pacient no. DNA sample Mutations/amplicons38 41 16 54 55 56 57
1 1 Biopsy - - - + - - -Faeces - - - + - - -
2 4 Biopsy - - - - - + -Faeces - - - - - + -
3 7 Biopsy - - - + - - -Faeces - - - + - - +
4 8 Biopsy - - - + - - -Faeces - - - + - - +
5 11 Biopsy - - - + - - +Faeces - - - + - - +
6 13 Biopsy - - - + - - +Faeces - - - + - - -
7 14 Biopsy - - - - - + -Faeces - - - - - + -
8 16 Biopsy - - - + - - -Faeces - - - + - - -
9 17 Biopsy - - - - - + -Faeces - - - + - + -
10 20 Biopsy - - - - - + -Faeces - - - - - + -
11 21 Biopsy - - - + - - -Faeces - - - + - - +
12 26 Biopsy - - - + - + -Biopsy - - - + - + -
13 29 Faeces - - - + - + -Biopsy - - - + - + -
14 34 Biopsy - - - + - + -Faeces - - - + + -
15 38 Biopsy - - - + - - -
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No. Pacient no. DNA sample Mutations/amplicons38 41 16 54 55 56 57
Biopsy - - - + - - -
16 46 Faeces - - - + -Biopsy - - - + - + -
17 48 Biopsy - - - + - - -Faeces - - - + -
18 56 Biopsy - - - - - + -Faeces - - - + -
19 59 Biopsy - - - + - + -Faeces - - - - - + -
20 74 Biopsy - - - - - + +Faeces - - - - - + -
21 78 Biopsy - - - + - - -Faeces - - - + -
22 84 Biopsy - - - + - - -Biopsy - - - + - - -
23 89 Faeces - - - + -Biopsy - - - + - - -
24 93 Biopsy - - - + - - -Faeces - - - + -
25 96 Biopsy - - - + - + -Biopsy - - - + - - -
26 104 Faeces - - - + +Biopsy - - - + - - +
27 107 Biopsy - - - + - - -Faeces - - - + - - -
28 109 Biopsy - - - - - + -Faeces - - - - - +
29 116 Biopsy - - - + - - -Biopsy - - - + - - -
30 119 Faeces - - - + - - -Biopsy - - - + - - -
31 121 Biopsy - - - + - + -Faeces + - - -
32 129 Biopsy - - - + - - +Faeces - - - + - - +
33 132 Biopsy - - - + - - -Faeces - - - + - - -
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No. Pacient no. DNA sample Mutations/amplicons38 41 16 54 55 56 57
34 134 Biopsy - - - + - + -Faeces - - - + - - -
35 138 Biopsy - - - + - - -Faeces - - - + - - -
36 143 Biopsy - - - + - + -Biopsy - - - + - + -
37 146 Faeces - - - - - + -Biopsy - - - - - + -
38 147 Biopsy - - - + - - -Faeces - - - + - - -
39 159 Biopsy - - - - - + -Biopsy - - - - - + -
40 166 Faeces - - - + - + -Biopsy - - - + - + +
41 168 Biopsy - - - + - + -Faeces - - - + - + -
42 171 Biopsy - - - - - + -Faeces - - - - - + -
43 177 Biopsy - - - + - - -Biopsy - - - + - - -
44 179 Faeces - - - + - - -Biopsy - - - + - - -
45 182 Biopsy - - - + - - +Faeces - - - + - - +
46 189 Biopsy - - - + - - -Faeces - - - + - - -
47 201 Biopsy - - - + - - -Faeces - - - + - - -
48 203 Biopsy - - - + - - -Faeces + - - -
49 208 Biopsy - - - + - - -Faeces - - - + - - -
50 211 Biopsy - - - + - - -Biopsy - - - + - - -
51 220 Faeces - - - - - + +Biopsy - - - - - + +
52 224 Biopsy - - - + - - -
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No. Pacient no. DNA sample Mutations/amplicons38 41 16 54 55 56 57
Faeces - - - + - - -
53 228 Biopsy - - - - - - -Biopsy - - - - - - -
54 230 Faeces - - - +Biopsy - - - + - - -
55 236 Biopsy - - - + - - -Faeces - - - + - - -
56 237 Biopsy - - - + - - +Faeces - - - + - - -
57 211 Biopsy - - - - - - +Biopsy - - - - - - +
58 220 Faeces + -Biopsy - - - + - - -
59 224 Biopsy - - - + - - +Faeces + +
60 228 Biopsy - - - + - - -Faeces - - - + - - -
61 230 Faeces - - - - - - +Biopsy - - - - - - +
62 236 Biopsy - - - + - - -Faeces - - - + - - -
63 237 Biopsy - - - + - - -Faeces - - - + - - -
64 238 Biopsy - - - + - - -Faeces - - - + - - -
65 241 Biopsy - - - - - - +Biopsy - - - - - - +
66 244 Faeces - - - + - - +Biopsy - - - + - - +
67 248 Biopsy - - - + - - -Faeces - - - - - - -
68 249 Biopsy - - - + - - -Faeces - - - + - - -
69 250 Faeces - - - + - - -Biopsy - - - + - - -
Table 5. Patients with COL11A1 gene mutations
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We also noticed the same pattern of different speed migration in case of HE analysis of exon
56 in 18 patients (7.20%) and exon 57 in 11 patients (4.40%).
Statistic analysis revealed that the last two kind of mutations were correlated with tumor stage
IV, male gender and advanced age (> 70 yrs old) – table 6.
Histopathological and clinical features COL11A1 mutations (No./%)
Adenocarcinoma
Stage TNM I
Stage TNM II
Stage TNM III
Stage TNM IV
2 [2.89]
18 [26.08]
27 [39.13]
3 [4.34]
Advanced adenoma
High-grade dysplasia
VillousVillous adenoma
Tubular adenoma ≥1cm
0
1 [1.44]
1 [1.44]
Minor polyps
Tubular adenoma <1cm
HyperplasticHyperplastic
Unspecified
0
0
0
Age
(only for exon 56, 57)
> 70 yrs
(p=0.0478, 95%CI 11.781-49.552)
Gender ratio M/F=3.72(p=0.021, 95%CI 26.330-49.312)
EthnicityEthnicity CaucasianCaucasian/other(p=0.0037, 95%CI 14.114-49.226)
Localisation Descendent/Sigmoid(p=0.02, 95%CI 29.481-50.227)
TNM classification Stage II/III(p=0.009, 95%CI 7.336-39.386)
Table 6. Correlation between hiistopathological examination and genetic analysis.
The migrating front presented two bands, out of which the slowest part generates the hetero‐
duplexes obtained through denaturation-renaturation, and the faster one, the homoduplexes
(figure 3).
The samples were different from the wild type due to the fact that they contain amplified
mutant type DNA, which through electrophoresis leads to speed migration modification.
The mutation detected by us is a substitutive type one as a series of 2 bands was evident on
the migration front.
There were no seen mutations for the rest of the analyzed cases for the exon 55.
All detected mutations can be observed in table no. 5
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Among 229 patients with advanced neoplasia (tubular adenoma 1 cm in diameter or larger,
villous polyp, polyps with high-grade dysplasia, or cancer), 69 patients (27.60%) presented
mutations in COL11A1 gene in at least 1 exon (table no. 5 and 6).
Regarding benign polyps, none of patients presented COL11A1 mutations.
19. Disscusions and conclusions
COL11A1 gene overexpression has been implicated as a candidate marker of various types of
cancers [26]. Previous studies have found overexpression of the COL11A1 gene in different
types of cancers, such as non-small cell lung (NSCLC), ovarian, oral cavity and colorectal
cancers [13-16]. In particular, overexpression of the COL11A1 gene was found to be correlated
with invasion and metastasis of these cancers [13-16].
As we previously detected in a pilot study regarding genetic mutations related to COL11A1
gene in exfoliated epithelial cells in the stool, we found mutations involving exon 54 [27].
L – molecular weight ladder. M – healthy individual allele (control). P – unprocessed allele for exon 54. M+P – dena‐
tured-renatured sample.
Figure 3. Electrophoresis in 6% polyacrylamid gel of the processed samples in order to point out heteroduplexes for
exon 54, using silver staining.
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Our present study confirmed the presence of COL11A1 mutations in patients with colorectal
adenomas or cancer. Polyacrylamide gel electrophoresis method for the heteroduplex analysis
(HA) was a sensitive genetic method to diagnose mutations of COL11A1.
Mutations detected in biopsy cells were present in exfoliated cells from feaces, proving the
usefulness of this genetic approach for noninvasive early diagnosis. Genetic alterations were
detected at the level of exons 54, 56 and 57.
Our results are similar with the results of other studies which have previously shown that
COL11A1 is upregulated in the majority of sporadic colorectal cancer [28], emphasizing the
fact that the expression of COL11A1 could be the primary change giving rise to a tumorigenic
response in epithelial cells [28].
1. Another study found a statistically significant overexpression of COL11A1 in polyps from
a patient with FAP [29]. The results from this study suggested that the expression of
COL11A1 could directly contribute to tumorigenesis in fibroblasts in FAP and explain
osteomas and desmoids, or indirectly to polyp-formation and tumor progression in
sporadic CRC [29].
2. The study of Croner R et al [30] also showed up-regulation of COL11A1 in CRC versus
normal colonic mucosa (p<0.001). The same result was shown by Lascorz et al study, in
which extracellular matrix receptor interaction and focal adhesion shared nine genes
(COL1A1, COL1A2, COL3A1, COL4A1, COL11A1, FN1, ITGA2, SPP1, and THBS2) were
upregulated in colorectal cancer [31].
Joined by other well known genetic tools already examined in the stool cell’s DNA involved
in the development of some colorectal cancers, COL11A1 could be a feasible genetic biomarker
targeted in stool samples for early diagnosis of colorectal cancer at risk patients.
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